摘要
CD19嵌合抗原受体T细胞疗法是治疗B细胞血液肿瘤的新兴免疫疗法,并取得了较好的疗效。随着其使用的增加,免疫效应细胞相关细胞因子释放综合征的发生率也相应升高,迫切需要对其精确机制和治疗进行进一步的临床研究。文章总结了细胞因子释放综合征的机制、临床表现、分级系统、治疗以及管理策略。
CD19 chimeric antigen receptor T cells(CAR-T)therapy is a new immunotherapy for B-cell hematological tumors,and has good efficacy.With the increase of its use,the incidence of immune effector cell-associated cytokine release syndrome is increasing,and further clinical research on its precise mechanism and treatment is urgently needed.This review summarizes the mechanisms,clinical manifestations,grading systems,treatments and management strategies of cytokine release syndrome.
作者
张琪
殷国桓
肖毅
Zhang Qi;Yin Guohuan;Xiao Yi(Department of Hematology,Tongji Hospital,Tongji Medical College,Huazhong University of Science and Technology,Wuhan 430030,China;Institute of Basic Medical Sciences,Chinese Academy of Medical Sciences&Peking Union Medical College,Beijing 100730,China)
出处
《白血病.淋巴瘤》
CAS
2021年第9期568-571,共4页
Journal of Leukemia & Lymphoma
基金
国家自然科学基金(82070213)
湖北省重点研发计划(2020BCB021)。